FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894042521> ?p ?o ?g. }

• W2894042521 endingPage "e29" @default.
• W2894042521 startingPage "20" @default.
• W2894042521 abstract "Abstract Lessons Learned Pazopanib shows a modest efficacy in metastatic alveolar soft part sarcoma. Clinical outcomes were comparable to those in previous studies using antiangiogenic drugs. Further prospective studies evaluating the benefit of pazopanib in alveolar soft part sarcoma with a larger sample are warranted to validate results. Background Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignant tumor characterized by an unbalanced translocation, t(X;17)(p11.2;q25), which leads to the fusion of ASPSCR1 to the TFE3 transcription factor. Because this results in the upregulation of angiogenesis-related transcripts, antiangiogenic drugs have been used in ASPS patients. Methods This open-label, single-arm, multicenter, investigator-initiated phase II trial was designed to evaluate efficacy and safety of pazopanib 800 mg once daily in patients with metastatic ASPS. The primary endpoint was investigator-assessed overall response rate (ORR), and secondary endpoints were toxicity, progression-free survival (PFS), and overall survival (OS). 68Ga-RGD (Arg-Gly-Asp) positron emission tomography (PET) scan and gene expression profiling using NanoString platform were performed for biomarker analysis. Results Six patients with histologically confirmed metastatic ASPS were enrolled between December 2013 and November 2014. Among six patients, one achieved a partial response (PR) (ORR 16.7%) and five patients showed stable disease (SD). With a median follow-up of 33 months (range 18.7–39.3 months), median PFS was 5.5 months (95% confidence interval [CI] 3.4–7.6 months), and median OS was not reached. There were no severe toxicities except one patient with grade 3 diarrhea. Conclusion Pazopanib showed modest antitumor activity with manageable toxicities for patients with metastatic ASPS." @default.
• W2894042521 created "2018-10-05" @default.
• W2894042521 creator A5016978421 @default.
• W2894042521 creator A5020847797 @default.
• W2894042521 creator A5024891671 @default.
• W2894042521 creator A5044075250 @default.
• W2894042521 creator A5058521062 @default.
• W2894042521 creator A5061987787 @default.
• W2894042521 creator A5080295544 @default.
• W2894042521 creator A5083759602 @default.
• W2894042521 date "2018-09-25" @default.
• W2894042521 modified "2023-10-18" @default.
• W2894042521 title "A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma" @default.
• W2894042521 cites W1769310585 @default.
• W2894042521 cites W2003278910 @default.
• W2894042521 cites W2012921981 @default.
• W2894042521 cites W2028103272 @default.
• W2894042521 cites W2091695364 @default.
• W2894042521 cites W2099022883 @default.
• W2894042521 cites W2101776780 @default.
• W2894042521 cites W2107230638 @default.
• W2894042521 cites W2122492414 @default.
• W2894042521 cites W2133365073 @default.
• W2894042521 cites W2136894804 @default.
• W2894042521 cites W2250372 @default.
• W2894042521 cites W2517108090 @default.
• W2894042521 cites W2529083835 @default.
• W2894042521 cites W2595826871 @default.
• W2894042521 cites W4238034382 @default.
• W2894042521 cites W4378347307 @default.
• W2894042521 doi "https://doi.org/10.1634/theoncologist.2018-0464" @default.
• W2894042521 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324645" @default.
• W2894042521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30254189" @default.
• W2894042521 hasPublicationYear "2018" @default.
• W2894042521 type Work @default.
• W2894042521 sameAs 2894042521 @default.
• W2894042521 citedByCount "27" @default.
• W2894042521 countsByYear W28940425212019 @default.
• W2894042521 countsByYear W28940425212020 @default.
• W2894042521 countsByYear W28940425212021 @default.
• W2894042521 countsByYear W28940425212022 @default.
• W2894042521 countsByYear W28940425212023 @default.
• W2894042521 crossrefType "journal-article" @default.
• W2894042521 hasAuthorship W2894042521A5016978421 @default.
• W2894042521 hasAuthorship W2894042521A5020847797 @default.
• W2894042521 hasAuthorship W2894042521A5024891671 @default.
• W2894042521 hasAuthorship W2894042521A5044075250 @default.
• W2894042521 hasAuthorship W2894042521A5058521062 @default.
• W2894042521 hasAuthorship W2894042521A5061987787 @default.
• W2894042521 hasAuthorship W2894042521A5080295544 @default.
• W2894042521 hasAuthorship W2894042521A5083759602 @default.
• W2894042521 hasBestOaLocation W28940425211 @default.
• W2894042521 hasConcept C121608353 @default.
• W2894042521 hasConcept C126322002 @default.
• W2894042521 hasConcept C141071460 @default.
• W2894042521 hasConcept C142724271 @default.
• W2894042521 hasConcept C143998085 @default.
• W2894042521 hasConcept C203092338 @default.
• W2894042521 hasConcept C2777666782 @default.
• W2894042521 hasConcept C2778256501 @default.
• W2894042521 hasConcept C2778439243 @default.
• W2894042521 hasConcept C2778629024 @default.
• W2894042521 hasConcept C2779490328 @default.
• W2894042521 hasConcept C2779984678 @default.
• W2894042521 hasConcept C31760486 @default.
• W2894042521 hasConcept C535046627 @default.
• W2894042521 hasConcept C71924100 @default.
• W2894042521 hasConceptScore W2894042521C121608353 @default.
• W2894042521 hasConceptScore W2894042521C126322002 @default.
• W2894042521 hasConceptScore W2894042521C141071460 @default.
• W2894042521 hasConceptScore W2894042521C142724271 @default.
• W2894042521 hasConceptScore W2894042521C143998085 @default.
• W2894042521 hasConceptScore W2894042521C203092338 @default.
• W2894042521 hasConceptScore W2894042521C2777666782 @default.
• W2894042521 hasConceptScore W2894042521C2778256501 @default.
• W2894042521 hasConceptScore W2894042521C2778439243 @default.
• W2894042521 hasConceptScore W2894042521C2778629024 @default.
• W2894042521 hasConceptScore W2894042521C2779490328 @default.
• W2894042521 hasConceptScore W2894042521C2779984678 @default.
• W2894042521 hasConceptScore W2894042521C31760486 @default.
• W2894042521 hasConceptScore W2894042521C535046627 @default.
• W2894042521 hasConceptScore W2894042521C71924100 @default.
• W2894042521 hasIssue "1" @default.
• W2894042521 hasLocation W28940425211 @default.
• W2894042521 hasLocation W28940425212 @default.
• W2894042521 hasLocation W28940425213 @default.
• W2894042521 hasLocation W28940425214 @default.
• W2894042521 hasOpenAccess W2894042521 @default.
• W2894042521 hasPrimaryLocation W28940425211 @default.
• W2894042521 hasRelatedWork W2085866999 @default.
• W2894042521 hasRelatedWork W2588544019 @default.
• W2894042521 hasRelatedWork W2740911849 @default.
• W2894042521 hasRelatedWork W2894042521 @default.
• W2894042521 hasRelatedWork W2905230616 @default.
• W2894042521 hasRelatedWork W2921652393 @default.
• W2894042521 hasRelatedWork W3037583503 @default.
• W2894042521 hasRelatedWork W3042055329 @default.
• W2894042521 hasRelatedWork W3088622637 @default.

• next